ResMed Q2 FY2022: Revenue $894.9M (+12% YoY), GAAP EPS $1.37, non-GAAP $1.47; dividend $0.42

RESMED INC

2022-Q2 EPS reported $2.76 revenue$1,798,890,000

Revenue $894.9M, up 12% YoY (13% constant currency); operating income $248.7M, up 12%.
GAAP diluted EPS $1.37 (up 11%); non-GAAP diluted EPS $1.47 (up 4%).
Gross margin contracted 140 bps GAAP to 56.4%; non-GAAP gross margin down 230 bps to 57.6%.
Board declared quarterly cash dividend $0.42/share, payable March 17, 2022, record date Feb 10.
CEO cited strong demand from competitor device recall, ongoing supply chain constraints.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.